Deploy accurate NGS testing with Omicia’s Opal Clinical™
The variant interpretation and reporting platform of choice for the UK 100,000 Genomes Project, LabCorp and clinical labs worldwide.
Accurately report on causative variants from
gene panels, exomes, and whole genomes.
Omicia’s Opal Clinical system is a robust, scalable platform
developed in collaboration with leading testing labs to accelerate
the clinical interpretation of NGS data.
Learn how your lab can optimize report turnaround time and increase diagnostic yield with NGS testing. Schedule a free Opal demo today.
Multiple NGS Testing Analysis Options
Opal Clinical’s robust functionality allows labs to deploy and interpret clinical tests on targeted gene panels, single exome and family exome tests.
Labs can launch condition-specific panels with established reimbursement such as: BRCA1/2; Illumina TruSight and Ion AmpliSeq ready-to-use panels; and custom gene panels.
Standardized Variant Interpretation
Opal Clinical’s intuitive interface and automated annotations enable labs to interpret NGS genomic data faster and with unprecedented accuracy.
Optimized for clinical testing labs, users can deploy standardized workflows to quickly identify and confirm already classified variants, and efficiently evaluate novel or unclassified variants.
Seamless Integration with Lab Workflow
From sample accession and CPT code assignment to LIS integration and EMR output, Opal Clinical facilitates rapid report turnaround.
Our CLIA and HIPAA-compliant platform produces physician-ready reports, seamlessly integrates into any lab’s workflow, and can interface with your LIS to ensure the fidelity of patient information and test results.
Omicia’s Opal NGS informatics, interpretation, and reporting platform provides labs with the key capabilities
to enable the application of genomics to routine diagnostics and personalized therapies.
Pioneers in genomics, diagnostics, and bioinformatics
Omicia’s leaders have proven track records, including senior roles on the Human Genome Project, at LabCorp, Merck, and Life Technologies.
We’ve built the Opal platform to deliver genomics-based solutions that expedite diagnoses, improve medical outcomes, and accelerate understanding of the genetic basis of disease. Meet our leaders >
Trusted by leaders in translational and clinical omics
Over 500 research, pharma, and clinical diagnostics labs rely on Omicia’s technological precision and clinical expertise.
Omicia’s algorithms have been developed in the lab, designed for the clinic, and have been validated in dozens of published research and clinical studies. Read our publications >